Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-03-20
2010-06-08
Haddad, Maher M (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S134100, C424S143100, C424S155100
Reexamination Certificate
active
07731963
ABSTRACT:
The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.
REFERENCES:
patent: 4777245 (1988-10-01), Foung et al.
patent: 5073492 (1991-12-01), Chen et al.
patent: 5858991 (1999-01-01), Hellerqvist et al.
patent: 6207642 (2001-03-01), Wiley
patent: 6448042 (2002-09-01), Greene
patent: 6492123 (2002-12-01), Holliger et al.
patent: 6544761 (2003-04-01), Greene et al.
patent: 6608048 (2003-08-01), Tsou et al.
patent: 6727225 (2004-04-01), Wiley
patent: 6824773 (2004-11-01), Wiley
patent: 6943146 (2005-09-01), Jakubowski et al.
patent: 7067475 (2006-06-01), Cerretti et al.
patent: 7074408 (2006-07-01), Fanslow, III et al.
patent: 7087725 (2006-08-01), Browning et al.
patent: 7109298 (2006-09-01), Browning et al.
patent: 7129061 (2006-10-01), Browning et al.
patent: 7208151 (2007-04-01), Browning et al.
patent: 2002/0004041 (2002-01-01), Albert et al.
patent: 2002/0042368 (2002-04-01), Fanslow et al.
patent: 2003/0100074 (2003-05-01), Yu et al.
patent: 2003/0148314 (2003-08-01), Berger et al.
patent: 2003/0162712 (2003-08-01), Cerretti et al.
patent: 2003/0170228 (2003-09-01), Ashkenazi et al.
patent: 2003/0198640 (2003-10-01), Yu et al.
patent: 2003/0211096 (2003-11-01), Ashkenazi et al.
patent: 2003/0211993 (2003-11-01), Jakubowski et al.
patent: 2003/0216546 (2003-11-01), Tykocinski
patent: 2003/0228305 (2003-12-01), Frantz et al.
patent: 2004/0014176 (2004-01-01), Ashkenzai et al.
patent: 2004/0018170 (2004-01-01), Shirwan
patent: 2004/0033495 (2004-02-01), Murray et al.
patent: 2004/0038349 (2004-02-01), Hilbert et al.
patent: 2004/0047854 (2004-03-01), Black et al.
patent: 2004/0076955 (2004-04-01), Mack et al.
patent: 2004/0091473 (2004-05-01), DuBose et al.
patent: 2004/0175744 (2004-09-01), Hu et al.
patent: 2004/0253610 (2004-12-01), Wiley
patent: 2005/0008636 (2005-01-01), Rennert
patent: 2005/0054047 (2005-03-01), Wiley
patent: 2005/0054568 (2005-03-01), Ling et al.
patent: 2005/0181375 (2005-08-01), Aziz et al.
patent: 2005/0208046 (2005-09-01), Kim et al.
patent: 2005/0208500 (2005-09-01), Erlander et al.
patent: 2006/0084143 (2006-04-01), Wiley
patent: 2006/0127397 (2006-06-01), Strittmatter
patent: 2007/0110745 (2007-05-01), Rennert
patent: 2007/0280940 (2007-12-01), Winkles et al.
patent: WO 96/18725 (1996-06-01), None
patent: WO 98/05783 (1998-02-01), None
patent: WO 98/35061 (1998-08-01), None
patent: WO 98/55508 (1998-12-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/19490 (1999-04-01), None
patent: WO 99/59614 (1999-11-01), None
patent: WO 99/61471 (1999-12-01), None
patent: WO 00/37638 (2000-06-01), None
patent: WO 00/42073 (2000-07-01), None
patent: WO 01/45730 (2001-06-01), None
patent: WO 01/53486 (2001-07-01), None
patent: WO 01/85193 (2001-11-01), None
patent: WO 03/086311 (2003-10-01), None
patent: WO 2006047172 (2006-05-01), None
patent: WO 2006096487 (2006-09-01), None
patent: WO 2006125632 (2006-11-01), None
patent: WO 2006130429 (2006-12-01), None
patent: WO 2009/140177 (2009-11-01), None
Schnieder et al. TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur J Immunol. Jun. 1999;29(6):1785-92.
Salloum et al., NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity. Cancer Res. Dec. 15, 2000;60(24):6958-63.
Abbas AK et al. (eds), Chapter Fifteen, “Immunity to Microbes”,Cellular and Molecular Immunology, Philadelphia: WB Saunders Co. pp. 302-314 (1991).
Abbas AK et al. (eds), Chapter One, “General Properties of Immune Responses”, Introduction to Immunology,Cellular and Molecular Immunology, Philadelphia: WB Saunders Co. pp. 4-12 (1991).
Ashkenazi and Dixit, “Death Receptors: Signaling and Modulation”,Science, vol. 281, pp. 1305-1308 (1998).
Bach-Elias et al., “Presence of autoantibodies against small nuclear ribonucleoprotein epitopes in Chagas' patients' sera”,Parasitol. Res., vol. 84, pp. 196-799 (1998).
Browning et al, “Characterization of surface lymphotoxin forms”J. Immunol, 154:33-46 (1995).
Cassiano et al., “Molecular Cloning of a Novel Receptor for TWEAK”,Scand. J. Immunol. 51 (Supp. 1) 1-111, 2001.
Chaplin and Fu, “Cytokine regulation of secondary lymphoid organ development”,Current Opinion in Immunology, vol. 10, pp. 288-297 (1998).
Chicheportiche et al. “Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies.”Arthritis Res. 2002;4(2):126-33. Epub Nov. 9, 2001.
Chicheportiche et al., “Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory Pathologies”,Biochem Biophys Res Commun., Dec. 9;279(1):162-5 (2000).
Chicheportiche et al., “TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis.”J Biol Chem., 272(51):32401-10, (Dec. 19, 1997).
Colman PM, “Effects of amino acid sequence changes on antibody-antigen interactions,”Res. Immunol.145(1):33-36 (1994).
Dallman, “Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult”,Current Opinion in Immunology, vol. 7, pp. 632-638 (1995).
De Wit et al., “Preferential Activation of Th2 Cells in Chronic Graft-versus-Host Reaction”,The Journal of Immunology, col. 150 (2), pp. 361-366 (1993).
Desplat-Jégo et al., “TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity,”Journal of Neuroimmunology, 133:116-123 (2002).
Donohue et al., “TWEAK Is an Endothelial Cell Growth and Chemotactic Factor That Also Potentiates FGF-2 and VEGF-A Mitogenic Activity,”Arterioscler. Thromb. Vasc. Biol., 23:594-600 (2003).
Durie et al., “Antibody to the Ligand of CD40, gp39, Blocks the Occurrence of the Acute and Chronic Forms of Graft-vs-Host Disease”,J. Clin. Invest., vol. 94, pp. 1333-1338 (1994).
Feng et al., “The Fn 14 Immediate-Early Response Gene Is Induced During Liver Regeneration and Highly Expressed in Both Human and Murine Hepatocellular Carcinomas,”American Journal of Pathology, 156(4):1253-1261 (Apr. 2000).
Ferrara et al., “The Biology of Vascular Endothelial Growth Factor,”Endocr. Rev., 18(1):4-25 (1997).
Flynn et al., “CD4 T Cell Cytokine Differentiation: The B Cell Activation Molecule, OX40 Ligand, Instructs CD4 T Cells to Express Interleukin 4 and Upregulates Expression of the Chemokine Receptor, Blr-1”,J. Exp. Med., vol. 188, pp. 297-304 (1998).
Grewal and Flavell, “The CD40 Ligand”,Immunol. Res., vol. 16, pp. 59-70 (1997).
Grewal and Flavell, “The Role of CD40 Ligand in Costimulation and T-Cell Activation”,Immunol. Rev., vol. 153, pp. 85-106 (1996).
Hahm et al., “TWEAK overexpression induces hyperplasia in liver and kidney,”FASEB J., Abstract # 471.5, vol. 17, No. 4-5 (Mar. 2003).
Han et al., “Identification of Differentially Expressed Genes in Pancreatic Cancer Cells Using cDNA Microarray,”Cancer Research, 62:2890-2896 (May 15, 2002).
Ho et al., “Soluble Tumor Necrosis Factor-Like Weak Inducer of Apoptosis Overexpression in HEK293 Cells Promotes Tumor Growth and Angiogenesis in Athymic Nude Mice,”Cancer Research, 64:8968-8972 (Dec. 15, 2004).
Jakubowski et al., “TWEAK induces liver progenitor cell proliferation,”J. Clin. Invest., 115(9):2330-2340 (Sep. 2005).
Jakubowski, “Dual Role for TWEAK in angiogenic regulation”J. Cell Science, 115:267-274 (2002).
Jakubowski,, “TWEAK Synergizes with Basis Fibroblast Growth Factor to Induce Endothelial Cell Proliferation, Migration and Lumen Morphogenesis”,Scand. J. Immunol., 51:Sup. 1:62 (2000).
Kaduka et al., “TWEAK mediates anti-tumor effect of tumor-infiltrating macrophage,”Biochemical and Biophysical Research Communications, 331
Browning Jeffrey
Burkly Linda
Jakubowski Aniela
Zheng Timothy
Biogen Idec MA Inc.
Fish & Richardson P.C.
Haddad Maher M
LandOfFree
TWEAK receptor agonists as anti-angiogenic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TWEAK receptor agonists as anti-angiogenic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TWEAK receptor agonists as anti-angiogenic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4225991